ReviewPharmacology & therapeutics2020
Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.
Review in Pharmacology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 65 citations in OpenAlex.
- Nanoparticle technologies in precision oncology and personalized vaccine development: Challenges and advances.International journal of pharmaceutics: X · 2025Review
- Pyroptosis and chemical classification of pyroptotic agents.Molecular diversity · 2025Review
- An injectable gambogic acid loaded nanocomposite hydrogel enhances antitumor effect by reshaping immunosuppressive tumor microenvironment.Materials today. Bio · 2025Article
- Tumor immunomodulation by nanoparticle and focused ultrasound alters gut microbiome in a sexually dimorphic manner.Theranostics · 2025Article
- Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments.Cancer medicine · 2024Review
- Treating Deep-Seated Tumors with Radiodynamic Therapy: Progress and Perspectives.Pharmaceutics · 2024Review
- Enabling Chemo-Immunotherapy with HIFU in Canine Cancer Patients.Annals of biomedical engineering · 2024Article
- Review
- Irradiated engineered tumor cell-derived microparticles remodel the tumor immune microenvironment and enhance antitumor immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Age-associated changes in the gut microbiome impact efficacy of tumor immunomodulatory treatments.Experimental gerontology · 2023Article
- Pyroptosis Provides New Strategies for the Treatment of Cancer.Journal of Cancer · 2023Review
- Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer.Frontiers in oncology · 2022Review
- Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy.Nanoscale horizons · 2021Review
- Nanocarriers as a Tool for the Treatment of Colorectal Cancer.Pharmaceutics · 2021Review
- Nanotechnology synergized immunoengineering for cancer.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021Review
- Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?Theranostics · 2021Review
- An Updated Review on Silver Nanoparticles in Biomedicine.Nanomaterials (Basel, Switzerland) · 2020Review
- Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics.Frontiers in chemistry · 2020Review
- Targeting CXCR4 in AML and ALL.Frontiers in oncology · 2020Review
- Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chemotherapy, surgery, and radiation are accepted as the preferred treatment modalities against cancer, but in recent years the use of immunotherapeutic approaches has gained prominence as the fourth treatment modality in cancer patients. In this approach, a patient's innate and adaptive immune systems are activated to achieve clearance of occult cancerous cells. In this review, we discuss the preclinical and clinical immunotherapeutic (e.g., immunoadjuvants (in-situ vaccines, oncolytic viruses, CXC antagonists, device activated agents), organic and inorganic nanoparticles, and checkpoint blockade) that are under investigation for cancer therapy and diagnostics. Additionally, the innovations in imaging of immune cells for tracking therapeutic responses and limitations (e.g., toxicity, inefficient immunomodulation, etc.) are described. Existing data suggest that if immune therapy is optimized, it can be a real and potentially paradigm-shifting cancer treatment frontier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.